静脈血栓塞栓症治療機器の世界市場：洞察、競合情勢、市場予測：2032年

静脈血栓塞栓症治療機器の市場規模は、2025年から2032年までの予測期間中にCAGR 8.31％で成長すると予測されています。静脈血栓塞栓症（VTE）治療機器市場全体は、いくつかの収束要因により大幅な成長を遂げています。深部静脈血栓症（DVT）や肺塞栓症（PE）の罹患率の上昇は、人口の高齢化、座りがちなライフスタイル、慢性疾患などに起因しており、効果的な治療ソリューションに対する需要を大幅に押し上げています。外科手術や入院の増加はVTEのリスクを高めるため、予防・治療機器が必要とされています。さらに、血栓塞栓イベントの確立された危険因子であるがんの有病率の上昇が、高度なVTE治療の必要性をさらに高めています。これと相まって、主要市場参入企業による継続的な製品開発と技術革新がVTEデバイスの有効性とアクセシビリティを高め、2025年から2032年までの予測期間中の市場成長を後押ししています。

静脈血栓塞栓症治療機器市場力学：

Thrombosis UKが提供したデータ（2023年）によると、英国では静脈血栓塞栓症患者の55～60％近くが入院中または入院後に発生しています。

さらに、NSW政府機関（2023年）が提供したデータによると、オーストラリアでは毎年約1万4,000人が静脈血栓塞栓症を発症しています。静脈血栓塞栓症は、静脈内に血栓が形成されることで発症する、重篤で生命を脅かす可能性のある病状です。この臨床的緊急性が、下大静脈フィルター、機械的血栓除去装置、吸引システム、カテーテル指向性血栓溶解技術など、従来の抗凝固療法に代わる低侵襲性の先進的なVTE治療機器の普及に拍車をかけています。これらの機器は、標的を絞った血栓除去や回復時間の短縮を可能にするだけでなく、合併症を最小限に抑えることができるため、救急やインターベンションの現場でますます好まれるようになっています。

2024年に世界保健機関（WHO）から提供されたデータによると、国際がん研究機関（IARC）は、2022年に世界で2,000万件のがんが新たに登録されたと述べています。

さらに、世界保健機関（WHO）が2023年に発表したデータによると、世界全体で1,500万人以上の人々が脊髄損傷とともに暮らしています。脊髄手術を受ける患者は、長時間の不動、筋活動の低下、血管外傷を経験することが多く、これらすべてが血液のうっ滞を助長し、深部静脈血栓症や肺塞栓症の可能性を高める。同様に、がん患者は、悪性腫瘍に関連した炎症、腫瘍から分泌される凝固促進因子、化学療法の副作用などにより、凝固亢進状態に陥りやすく、VTEはがん医療における主要な合併症の一つとなっています。心不全、慢性腎臓病、炎症性腸疾患、自己免疫疾患などの慢性疾患は、持続的な全身性炎症、内皮機能障害、運動能力の低下を通じてVTEのリスクをさらに高めるため、静脈血栓塞栓症治療装置の市場全体を押し上げています。

さらに、世界中の主要市場参入企業による製品開発活動の活発化が、静脈血栓塞栓症治療機器の市場成長をさらに促進すると予想されます。例えば、2024年9月、Argon Medicalは、新しい血栓除去システムCLEANER Vacを発表しました。

したがって、上記の要因を総合すると、2025年から2032年までの予測期間中、静脈血栓塞栓症治療機器市場全体を牽引することになります。

しかし、これらの機器に関連するリスクや合併症、代替治療オプションの利用可能性などがエンドユーザー基盤を制限する可能性があり、静脈血栓塞栓症治療機器の成長を制限する主要な抑制要因として作用します。

静脈血栓塞栓症治療機器市場セグメント分析：

静脈血栓塞栓症治療機器市場：製品タイプ（圧迫システム、血栓除去システム、下大静脈フィルター、その他）、疾患タイプ別（深部静脈血栓症、肺塞栓症）、エンドユーザー別（病院・クリニック、外来手術センター、その他）、地域別（北米、欧州、アジア太平洋地域、その他の地域）

静脈血栓塞栓症治療機器市場の製品セグメントでは、圧迫システムカテゴリーが2024年に大きな収益シェアを獲得する見込みです。これは、このカテゴリーに関連する用途と利点に起因しています。圧迫システムは、特にリスクの高い患者人口において、深部静脈血栓症（DVT）の予防と管理のための効果的かつ非侵襲的で広く利用可能な方法を提供することにより、静脈血栓塞栓症（VTE）治療機器市場全体を押し上げる上で極めて重要な役割を果たしています。段階的圧迫ストッキング（GCS）や間欠的空気圧迫（IPC）装置を含むこれらのシステムは、静脈血流を促進し、静脈うっ滞を減少させ、血栓形成を予防する能力が実証されているため、病院、外来手術センター、在宅ヘルスケアの現場で採用が増加しています。

特に整形外科、脊椎外科、がん、心臓血管外科などの術後ケアでは、患者の運動機能が低下し、血栓形成のリスクが高まることが多いため、その有用性は極めて重要です。圧迫システムはまた、脳卒中、心不全、麻痺などの非外科的慢性疾患にも広く使用されており、その市場規模はさらに拡大しています。院内VTEのリスクに対する認識が高まるにつれ、ヘルスケア施設はこれらのシステムを標準的なVTE予防プロトコルに組み込んでおり、安定した需要を牽引しています。

圧力モニタリングや患者のコンプライアンス追跡機能を備えたスマートなウェアラブル圧迫装置の開発などの技術的進歩により、これらのシステムはより使いやすく、臨床的に効率的なものとなっています。さらに、主要市場参入企業の製品開拓活動の活発化が、圧迫システム市場全体をさらに押し上げています。例えば、2025年1月、中国を拠点とするメーカーが、ふくらはぎ、ふくらはぎ-大腿部、足部用に設計された間欠的空気圧迫（IPC）装置であるVenera 608深部静脈血栓症予防システムについて米国FDAから510（k）認可を取得しました。このシステムは、自然な歩行を模倣して血行を促進し、ソフトな膨張スリーブが付属しています。

したがって、上記のような要因がこのセグメントの市場全体を押し上げ、静脈血栓塞栓症市場全体を拡大させると予想されます。

すべての地域の中で、北米が2024年の静脈血栓塞栓症治療機器市場を独占すると予想されます。これは、がん患者、静脈血栓塞栓症、その他の慢性疾患の増加、製品開発および規制当局の承認における著しい進歩など、いくつかの要因によるものです。さらに、確立された洗練されたインフラの存在が、2025年から2032年までの予測期間中、静脈血栓塞栓症治療機器市場を牽引すると予想されます。

米国疾病予防管理センターのデータ（2025年）によると、米国では3分の1（約33％）の人が深部静脈血栓症（DVT）または肺塞栓症（PE）に罹患しており、10年以内に再発する可能性があるとされています。

これらの疾患の急増は、人口の高齢化、座りっぱなしの生活、肥満、がん、整形外科手術、特に入院患者や手術後の患者の長期の不動などの危険因子が主な原因です。このようなDVTやPEの増加により、効果的でタイムリーかつ安全な治療に対する緊急の臨床ニーズが高まっています。その結果、ヘルスケアプロバイダーは、下大静脈フィルター、カテーテル直接血栓溶解システム、機械的血栓除去装置、吸引血栓除去装置、間欠的空気圧迫（IPC）システムなどの先進的なVTE治療装置の採用を増やしています。これらの治療機器は、血栓の形成を予防し、既存の血栓を破壊し、肺への塞栓を予防するための重要なソリューションを提供し、地域全体の静脈血栓塞栓症治療機器市場を押し上げています。

さらに、Global Cancer Observatoryのデータ（2024年）によると、2022年には米国が全がん患者の89.1％を占め、カナダは同地域の全がん患者の10.9％を占めています。がんの罹患率の高さとそれに伴う凝固亢進性、静脈血栓塞栓症の再発率の高さが、静脈血栓塞栓症治療機器の需要を牽引しています。これらのデバイスはがん患者の重大な合併症に対処し、長期的な管理と転帰を向上させる。

さらに、主要市場参入企業による製品開発活動の活発化が、静脈血栓塞栓症治療装置の市場全体をさらに押し上げています。例えば、2024年11月、Cardinal Health社は、深部静脈血栓症および肺塞栓症予防のためのオールインワンソリューションを提供するKendall SCD SmartFlow圧迫システムを発売しました。

したがって、静脈血栓塞栓症治療機器市場における北米地域の成長環境は、前述のすべての要因の相互作用によって促進されるとみられています。

静脈血栓塞栓症治療装置市場の主要企業

静脈血栓塞栓症治療機器市場で事業を展開する主要な市場参入企業には、Abbott、Boston Scientific Corporation、AngioDynamics、Argon Medical Devices、Penumbra, Inc.、Thrombolex、Imperative Care Inc、Koninklijke Philips N.V.、Arjo、Stryker、Cook、BIOCOMPRESSION SYSTEMS、Medtronic、DSMAREF CO., LTD.、Teleflex Incorporated、Surmodics Inc.、ICE Aspiration System、VentiV Scientific、Inquis Medical、Cardinal Healthなどがあります。

静脈血栓塞栓症治療機器市場における最近の開発活動：

• 2024年10月、Surmodics Inc.は、Pounce XL血栓除去システムのFDA 510（k）認可を取得したと発表しました。
• 2024年4月、ICE Aspiration SystemがExpanse ICE Aspiration SystemのFDA 510（k）認可を取得。
• 2023年1月、Inari Medicaは、腸大腿部深部静脈血栓症（DVT）患者を対象としたクロットトリーバー・システムのDEFIANCE試験で最初の参加者を登録しました。

静脈血栓塞栓症治療機器市場調査レポートの主な内容

• 現在の静脈血栓塞栓症治療機器市場規模（2024年）と8年間（2025年～2032年）の市場予測に関する市場規模分析
• 過去3年間に起こった主な製品/サービス開発、合併、買収、提携、合弁事業など
• 静脈血栓塞栓症治療機器市場を独占する主要企業
• 静脈血栓塞栓症治療機器市場の競合他社が利用できるさまざまな機会
• 2024年に上位を占めるセグメントと2032年におけるこれらのセグメントの業績
• 現在の静脈血栓塞栓症治療機器市場のシナリオで上位を占める地域と国
• 企業が今後の静脈血栓塞栓症治療機器市場成長の機会に集中すべき地域と国

静脈血栓塞栓症治療機器市場のよくある質問

1.静脈血栓塞栓症治療機器

• 静脈血栓塞栓症とは、静脈内の血液が凝固する病気と定義され、診断がつかず、障害や死亡の原因となる深刻な、しかし予防可能な病気です。静脈血栓塞栓症治療機器は、塞栓症を治療するために体内に埋め込んだり挿入したりするデバイスです。

2.静脈血栓塞栓症治療機器市場

• 静脈血栓塞栓症治療機器市場は、2025年から2032年までの予測期間中にCAGR 8.31%で成長すると予測されています。

3.静脈血栓塞栓症治療機器市場の促進要因

• 静脈血栓塞栓症（VTE）治療機器市場全体は、いくつかの要因により大幅な成長を遂げています。高齢化、座りがちなライフスタイル、慢性疾患などに起因する深部静脈血栓症（DVT）および肺塞栓症（PE）の発生率の上昇が、効果的な治療ソリューションに対する需要を大幅に押し上げています。外科手術や入院の増加はVTEのリスクを高めるため、予防・治療機器が必要とされています。さらに、血栓塞栓イベントの確立された危険因子であるがんの有病率の上昇が、高度なVTE治療の必要性をさらに高めています。これと相まって、主要な市場参入企業別継続的な製品開拓と技術革新がVTEデバイスの有効性とアクセシビリティを高め、2025年から2032年までの予測期間中の市場成長を後押ししています。

4.静脈血栓塞栓症治療機器市場で事業を展開する主要企業

• 静脈血栓塞栓症治療機器市場で事業を展開している主な市場参入企業には、Abbott、Boston Scientific Corporation、AngioDynamics、Argon Medical Devices、Penumbra, Inc.、Thrombolex、Imperative Care Inc、Koninklijke Philips N.V.、Arjo、Stryker、Cook、BIOCOMPRESSION SYSTEMS、Medtronic、DSMAREF CO., LTD.、Teleflex Incorporated、Surmodics Inc.、ICE Aspiration System、VentiV Scientific、Inquis Medical、Cardinal Healthなどがあります。

5.静脈血栓塞栓症治療機器市場で最もシェアが高い地域

• すべての地域の中で、北米が2024年の静脈血栓塞栓症治療機器市場で大きな収益シェアを占めると推計されています。これは、がん患者の増加、静脈血栓塞栓症、製品開発および規制当局の承認における大幅な進歩など、いくつかの要因別ものです。さらに、確立された洗練されたインフラの存在が、2025年から2032年までの予測期間中に静脈血栓塞栓症治療機器市場を牽引すると予想されます。

目次

第1章 静脈血栓塞栓症治療機器市場レポートのイントロダクション

第2章 静脈血栓塞栓症治療機器市場のエグゼクティブサマリー

第3章 競合情勢

第4章 規制分析

• 米国
• 欧州
• 日本
• 中国

第5章 静脈血栓塞栓症治療機器市場の主な要因分析

• 静脈血栓塞栓症治療機器市場促進要因
  • 深部静脈血栓症および肺塞栓症の発生率の上昇
  • がんやその他の慢性疾患の増加により、外科手術や入院が増加
  • 世界中の主要市場参入企業による製品開発活動の増加
• 静脈血栓塞栓症治療機器市場抑制要因と課題
  • これらのデバイスに関連するリスクと合併症
  • 代替治療オプションの利用可能性
• 静脈血栓塞栓症治療機器の市場機会
  • 静脈血栓塞栓症治療機器の治療における血栓溶解療法と機械的アプローチの併用

第6章 静脈血栓塞栓症治療機器市場：ポーターのファイブフォース分析

第7章 静脈血栓塞栓治療デバイス市場評価

• 製品別
  • 圧縮システム
  • 血栓除去システム
  • 下大静脈フィルター
  • その他
• 疾患タイプ別
  • 深部静脈血栓症
  • 肺塞栓症
• エンドユーザー別
  • 病院と診療所
  • 外来手術センター
• 地域
  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第8章 静脈血栓塞栓症治療機器市場：企業と製品プロファイル

• Abbott
• Boston Scientific Corporation
• AngioDynamics
• Argon Medical Devices
• Penumbra, Inc.
• Thrombolex
• Imperative Care Inc.
• Koninklijke Philips N.V.
• Arjo
• Stryker
• Cook
• BIOCOMPRESSION SYSTEMS
• Medtronic
• DSMAREF CO.LTD
• Teleflex Incorporated
• Surmodics Inc.
• ICE Aspiration System
• VentiV Scientific
• Inquis Medical
• Cardinal Health

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Venous Thromboembolism Treatment Devices Market in Global (2022-2032)
• Table 3: Venous Thromboembolism Treatment Devices Market in Global by Product (2022-2032)
• Table 4: Venous Thromboembolism Treatment Devices Market in Global by Disease Type (2022-2032)
• Table 5: Venous Thromboembolism Treatment Devices Market in Global by End-User (2022-2032)
• Table 6: Venous Thromboembolism Treatment Devices Market in Global by Geography (2022-2032)
• Table 7: Venous Thromboembolism Treatment Devices Market in North America (2022-2032)
• Table 8: Venous Thromboembolism Treatment Devices Market in the United States (2022-2032)
• Table 9: Venous Thromboembolism Treatment Devices Market in Canada (2022-2032)
• Table 10: Venous Thromboembolism Treatment Devices Market in Mexico (2022-2032)
• Table 11: Venous Thromboembolism Treatment Devices Market in Europe (2022-2032)
• Table 12: Venous Thromboembolism Treatment Devices Market in France (2022-2032)
• Table 13: Venous Thromboembolism Treatment Devices Market in Germany (2022-2032)
• Table 14: Venous Thromboembolism Treatment Devices Market in United Kingdom (2022-2032)
• Table 15: Venous Thromboembolism Treatment Devices Market in Italy (2022-2032)
• Table 16: Venous Thromboembolism Treatment Devices Market in Spain (2022-2032)
• Table 17: Venous Thromboembolism Treatment Devices Market in Rest of Europe (2022-2032)
• Table 18: Venous Thromboembolism Treatment Devices Market in Asia-Pacific (2022-2032)
• Table 19: Venous Thromboembolism Treatment Devices Market in China (2022-2032)
• Table 20: Venous Thromboembolism Treatment Devices Market in Japan (2022-2032)
• Table 21: Venous Thromboembolism Treatment Devices Market in India (2022-2032)
• Table 22: Venous Thromboembolism Treatment Devices Market in Australia (2022-2032)
• Table 23: Venous Thromboembolism Treatment Devices Market in South Korea (2022-2032)
• Table 24: Venous Thromboembolism Treatment Devices Market in Rest of Asia-Pacific (2022-2032)
• Table 25: Venous Thromboembolism Treatment Devices Market in Rest of the World (2022-2032)
• Table 26: Venous Thromboembolism Treatment Devices Market in the Middle East (2022-2032)
• Table 27: Venous Thromboembolism Treatment Devices Market in Africa (2022-2032)
• Table 28: Venous Thromboembolism Treatment Devices Market in South America (2022-2032)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Venous Thromboembolism Treatment Devices Market in Global (2022-2032)
• Figure 3: Venous Thromboembolism Treatment Devices Market in Global by Product (2022-2032)
• Figure 4: Venous Thromboembolism Treatment Devices Market in Global by Disease Type (2022-2032)
• Figure 5: Venous Thromboembolism Treatment Devices Market in Global by End-User (2022-2032)
• Figure 6: Venous Thromboembolism Treatment Devices Market in Global by Geography (2022-2032)
• Figure 7: Venous Thromboembolism Treatment Devices Market in North America (2022-2032)
• Figure 8: Venous Thromboembolism Treatment Devices Market in the United States (2022-2032)
• Figure 9: Venous Thromboembolism Treatment Devices Market in Canada (2022-2032)
• Figure 10: Venous Thromboembolism Treatment Devices Market in Mexico (2022-2032)
• Figure 11: Venous Thromboembolism Treatment Devices Market in Europe (2022-2032)
• Figure 12: Venous Thromboembolism Treatment Devices Market in France (2022-2032)
• Figure 13: Venous Thromboembolism Treatment Devices Market in Germany (2022-2032)
• Figure 14: Venous Thromboembolism Treatment Devices Market in United Kingdom (2022-2032)
• Figure 15: Venous Thromboembolism Treatment Devices Market in Italy (2022-2032)
• Figure 16: Venous Thromboembolism Treatment Devices Market in Spain (2022-2032)
• Figure 17: Venous Thromboembolism Treatment Devices Market in Rest of Europe (2022-2032)
• Figure 18: Venous Thromboembolism Treatment Devices Market in Asia-Pacific (2022-2032)
• Figure 19: Venous Thromboembolism Treatment Devices Market in China (2022-2032)
• Figure 20: Venous Thromboembolism Treatment Devices Market in Japan (2022-2032)
• Figure 21: Venous Thromboembolism Treatment Devices Market in India (2022-2032)
• Figure 22: Venous Thromboembolism Treatment Devices Market in Australia (2022-2032)
• Figure 23: Venous Thromboembolism Treatment Devices Market in South Korea (2022-2032)
• Figure 24: Venous Thromboembolism Treatment Devices Market in Rest of Asia-Pacific (2022-2032)
• Figure 25: Venous Thromboembolism Treatment Devices Market in Rest of the World (2022-2032)
• Figure 26: Venous Thromboembolism Treatment Devices Market in the Middle East (2022-2032)
• Figure 27: Venous Thromboembolism Treatment Devices Market in Africa (2022-2032)
• Figure 28: Venous Thromboembolism Treatment Devices Market in South America (2022-2032)
• Figure 29: Market Drivers
• Figure 30: Market Barriers
• Figure 31: Marker Opportunities
• Figure 32: PORTER'S Five Force Analysis

Venous Thromboembolism Treatment Devices Market by Product (Compression System, Thrombectomy Systems, Inferior Vena Cava Filter, and Others), Disease Type (Deep Vein Thrombosis and Pulmonary Embolism), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the increasing incidence of deep vein thrombosis and pulmonary embolism, increasing surgical procedures and hospitalizations due to increasing cancer prevalence and other chronic disorders, and rising product developmental activities among the key market players globally.

The venous thromboembolism treatment devices market is estimated to grow at a CAGR of 8.31% during the forecast period from 2025 to 2032. The overall market for venous thromboembolism (VTE) treatment devices is witnessing substantial growth due to several converging factors. The increasing incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), driven by aging populations, sedentary lifestyles, and chronic illnesses, is significantly boosting demand for effective treatment solutions. Rising numbers of surgical procedures and hospitalizations elevate the risk of VTE, necessitating preventive and therapeutic devices. Additionally, the growing prevalence of cancer, an established risk factor for thromboembolic events, further amplifies the need for advanced VTE treatment. Coupled with this, continuous product development and innovation by key market players are enhancing the effectiveness and accessibility of VTE devices, collectively propelling market growth during the forecast period from 2025 to 2032.

Venous Thromboembolism Treatment Devices Market Dynamics:

According to the data provided by Thrombosis UK (2023), nearly 55%-60% of venous thromboembolism cases occur during or following hospitalization in the UK.

Additionally, as per the data provided by the NSW Government Organization (2023), approximately 14,000 Australians develop a venous thromboembolism each year. Venous thromboembolism is a serious and potentially life-threatening medical condition that occurs when a blood clot forms in a vein. This clinical urgency is fueling the adoption of advanced VTE treatment devices such as inferior vena cava (IVC) filters, mechanical thrombectomy devices, aspiration systems, and catheter-directed thrombolysis technologies, which offer minimally invasive alternatives to traditional anticoagulation therapy. These devices not only provide targeted clot removal and reduced recovery time but also minimize complications, making them increasingly preferred in emergency and interventional settings.

According to data provided by the World Health Organization in 2024, the International Agency for Research on Cancer (IARC) stated that 20 million new instances of cancer were registered in 2022 globally.

Additionally, according to the data provided by the World Health Organization (2023), globally, over 15 million people were living with spinal cord injury. Patients undergoing spinal surgeries often experience prolonged immobility, reduced muscle activity, and vascular trauma, all of which contribute to blood stasis and increase the likelihood of deep vein thrombosis and pulmonary embolism. Similarly, cancer patients are predisposed to a hypercoagulable state due to malignancy-related inflammation, tumor-secreted procoagulant factors, and chemotherapy side effects, making VTE one of the leading complications in oncology care. Chronic disorders such as heart failure, chronic kidney disease, inflammatory bowel disease, and autoimmune conditions further raise the risk of VTE through persistent systemic inflammation, endothelial dysfunction, and reduced mobility, thereby boosting the overall market of venous thromboembolism treatment devices.

Moreover, the increased product developmental activities among key market players across the globe are further expected to drive the market growth for venous thromboembolism treatment devices. For example, in September 2024, Argon Medical introduced a new thrombectomy system, the CLEANER Vac, which provided doctors with manual control over suction, ensuring precise clot removal.

Therefore, the factors stated above collectively will drive the overall venous thromboembolism treatment devices market during the forecast period from 2025 to 2032.

However, the risk and complications associated with these devices, availability of alternative treatment options, and others may limit their end-user base, thus acting as key constraints limiting the growth of the venous thromboembolism treatment devices.

Venous Thromboembolism Treatment Devices Market Segment Analysis:

Venous Thromboembolism Treatment Devices Market by Product (Compression System, Thrombectomy Systems, Inferior Vena Cava Filter, and Others), Disease Type (Deep Vein Thrombosis and Pulmonary Embolism), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World)

In the product segment of the venous thromboembolism treatment devices market, the compression system category is expected to amass a significant revenue share in the year 2024. This can be ascribed to the applications and advantages related to the category. Compression systems are playing a pivotal role in boosting the overall market of venous thromboembolism (VTE) treatment devices by offering an effective, non-invasive, and widely accessible method for the prevention and management of deep vein thrombosis (DVT), particularly in high-risk patient populations. These systems, which include graduated compression stockings (GCS) and intermittent pneumatic compression (IPC) devices, are increasingly adopted across hospitals, ambulatory surgical centers, and home healthcare settings due to their proven ability to enhance venous blood flow, reduce venous stasis, and prevent clot formation.

Their utility is particularly critical in post-operative care, especially following orthopedic, spinal, cancer, and cardiovascular surgery scenarios where patients often experience reduced mobility and an increased risk of thrombus formation. Compression systems are also widely used in non-surgical chronic conditions, such as stroke, heart failure, and paralysis, further expanding their market reach. With rising awareness about the risks of hospital-acquired VTE, healthcare facilities are integrating these systems into standard VTE prophylaxis protocols, thereby driving steady demand.

Technological advancements, such as the development of smart wearable compression devices with pressure monitoring and patient compliance tracking features, are making these systems more user-friendly and clinically efficient. Furthermore, the increase in product development activities among the key market players is further boosting the overall market of compression systems. For instance, in January 2025, a China-based manufacturer received 510(k) clearance from the U.S. FDA for its Venera 608 Deep Vein Thrombosis Prevention System, an intermittent pneumatic compression (IPC) device designed for calf, calf-thigh, and foot use. The system mimics natural walking to enhance circulation and comes with soft inflation sleeves.

Thus, the factors mentioned above are expected to boost the overall market of the segment, thereby escalating the overall market of venous thromboembolism.

North America is expected to dominate the overall venous thromboembolism treatment devices market:

Among all the regions, North America is expected to dominate the venous thromboembolism treatment devices market in the year 2024. This can be attributed to several factors such as the rising cancer cases, venous thromboembolism, and other chronic conditions, combined with significant advancements in product development & regulatory approvals. Additionally, the presence of well-established and sophisticated infrastructure is expected to drive the market for venous thromboembolism treatment devices during the forecast period from 2025 to 2032.

According to data from the Centers for Disease Control and Prevention (2025), stated that one-third (about 33%) of people were suffering from deep vein thrombosis (DVT) or pulmonary embolism (PE) in the US and may have a recurrence of the disease within 10 years.

The surge in these conditions is largely attributed to risk factors such as aging populations, sedentary lifestyles, obesity, cancer, orthopedic surgeries, and long-term immobility, especially in hospitalized or post-operative patients. This rise in DVT and PE cases is prompting urgent clinical demand for effective, timely, and safe treatment interventions. As a result, healthcare providers are increasingly adopting advanced VTE treatment devices, including inferior vena cava (IVC) filters, catheter-directed thrombolysis systems, mechanical and aspiration thrombectomy devices, and intermittent pneumatic compression (IPC) systems. These devices provide critical solutions to either prevent clot formation, break down existing clots, or prevent embolization to the lungs, thereby boosting the overall market of venous thromboembolism treatment devices across the region.

Additionally, according to Global Cancer Observatory's data (2024), in 2022, the US represented 89.1% of all cancer cases, and Canada represented 10.9% of all cancer cases in the region. The high incidence of cancer and its associated hypercoagulability, along with a significant recurrence rate of venous thromboembolism, are driving the demand for venous thromboembolism treatment devices. These devices address critical complications in cancer patients, enhancing long-term management and outcomes.

Additionally, the increase in product development activities among the key market players is further boosting the overall market of venous thromboembolism treatment devices. For instance, in November 2024, Cardinal Health launched the Kendall SCD SmartFlow compression system, which delivers an all-in-one solution for deep vein thrombosis and pulmonary embolism prevention

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American region in the venous thromboembolism treatment devices market.

Venous Thromboembolism Treatment Devices Market key players:

Some of the key market players operating in the venous thromboembolism treatment devices market include Abbott, Boston Scientific Corporation, AngioDynamics, Argon Medical Devices, Penumbra, Inc., Thrombolex, Imperative Care Inc., Koninklijke Philips N.V., Arjo, Stryker, Cook, BIOCOMPRESSION SYSTEMS, Medtronic, DSMAREF CO., LTD., Teleflex Incorporated, Surmodics Inc., ICE Aspiration System, VentiV Scientific, Inquis Medical, Cardinal Health, and others.

Recent Developmental Activities in the Venous Thromboembolism Treatment Devices Market:

• In October 2024, Surmodics Inc. announced it had received FDA 510(k) clearance for its Pounce XL thrombectomy system.
• In April 2024, the ICE Aspiration System received FDA 510(k) clearance for the Expanse ICE Aspiration System.
• In January 2023, Inari Medical enrolled the first participant in the DEFIANCE trial of its ClotTriever System in iliofemoral deep vein thrombosis (DVT) patients.

Key takeaways from the venous thromboembolism treatment devices market report study

• Market size analysis for current venous thromboembolism treatment devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the venous thromboembolism treatment devices market
• Various opportunities available for the other competitors in the venous thromboembolism treatment devices market space
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current venous thromboembolism treatment devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the venous thromboembolism treatment devices market growth in the future?

Target audience who can benefit from this venous thromboembolism treatment devices market report study

• Venous thromboembolism treatment devices product providers
• Research organizations and consulting companies
• Venous thromboembolism treatment devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in venous thromboembolism treatment devices
• Various end-users who want to know more about the venous thromboembolism treatment devices market and the latest developments in the venous thromboembolism treatment devices market

Frequently Asked Questions for the Venous Thromboembolism Treatment Devices Market:

1. What are venous thromboembolism treatment devices?

• The venous thromboembolism can be defined as the clotting of blood in the veins, which is an undiagnosed and serious, yet preventable condition that can cause disability and death. Venous thromboembolism treatment devices are devices that can be either implanted or inserted into the body to treat embolism.

2. What is the market for venous thromboembolism treatment devices?

• The venous thromboembolism treatment devices market is estimated to grow at a CAGR of 8.31% during the forecast period from 2025 to 2032.

3. What are the drivers for the venous thromboembolism treatment devices market?

• The overall market for venous thromboembolism (VTE) treatment devices is witnessing substantial growth due to several converging factors. The increasing incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE), driven by aging populations, sedentary lifestyles, and chronic illnesses, is significantly boosting demand for effective treatment solutions. Rising numbers of surgical procedures and hospitalizations elevate the risk of VTE, necessitating preventive and therapeutic devices. Additionally, the growing prevalence of cancer, an established risk factor for thromboembolic events, further amplifies the need for advanced VTE treatment. Coupled with this, continuous product development and innovation by key market players are enhancing the effectiveness and accessibility of VTE devices, collectively propelling market growth during the forecast period from 2025 to 2032.

4. Who are the key players operating in the venous thromboembolism treatment devices market?

• Some of the key market players operating in the venous thromboembolism treatment devices market include Abbott, Boston Scientific Corporation, AngioDynamics, Argon Medical Devices, Penumbra, Inc., Thrombolex, Imperative Care Inc., Koninklijke Philips N.V., Arjo, Stryker, Cook, BIOCOMPRESSION SYSTEMS, Medtronic, DSMAREF CO., LTD., Teleflex Incorporated, Surmodics Inc., ICE Aspiration System, VentiV Scientific, Inquis Medical, Cardinal Health, and others.

5. Which region has the highest share in the venous thromboembolism treatment devices market?

• Among all the regions, North America is estimated to hold a significant revenue share in the venous thromboembolism treatment devices market in 2024. This can be attributed to several factors, such as the rising cancer cases, venous thromboembolism, combined with significant advancements in product development & regulatory approvals. Additionally, the presence of well-established and sophisticated infrastructure is expected to drive the market for venous thromboembolism treatment devices during the forecast period from 2025 to 2032.

Table of Contents

1. Venous Thromboembolism Treatment Devices Market Report Introduction

• 1.1. Scope of the Study
• 1.2. Market Segmentation
• 1.3. Market Assumption

2. Venous Thromboembolism Treatment Devices Market Executive Summary

• 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

• 4.1. The United States
• 4.2. Europe
• 4.3. Japan
• 4.4. China

5. Venous Thromboembolism Treatment Devices Market Key Factors Analysis

• 5.1. Venous Thromboembolism Treatment Devices Market Drivers
  • 5.1.1. Increasing incidence of deep vein thrombosis and pulmonary embolism
  • 5.1.2. Increasing surgical procedures and hospitalizations due to increasing cancer prevalence and other chronic disorders
  • 5.1.3. Rising product development activities among the key market players globally
• 5.2. Venous Thromboembolism Treatment Devices Market Restraints and Challenges
  • 5.2.1. Risk and complications associated with these devices
  • 5.2.2. Availability of alternative treatment options
• 5.3. Venous Thromboembolism Treatment Devices Market Opportunities
  • 5.3.1. Combined thrombolytic and mechanical approaches for the treatment of venous thromboembolism treatment devices

6. Venous Thromboembolism Treatment Devices Market Porter's Five Forces Analysis

• 6.1. Bargaining Power of Suppliers
• 6.2. Bargaining Power of Consumers
• 6.3. Threat of New Entrants
• 6.4. Threat of Substitutes
• 6.5. Competitive Rivalry

7. Venous Thromboembolism Treatment Devices Market Assessment

• 7.1. By Product
  • 7.1.1. Compression System
  • 7.1.2. Thrombectomy Systems
  • 7.1.3. Inferior Vena Cava Filter
  • 7.1.4. Others
• 7.2. By Disease Type
  • 7.2.1. Deep Vein Thrombosis
  • 7.2.2. Pulmonary Embolism
• 7.3. By End-User
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Ambulatory Surgical Centers
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.1.2. Canada Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.1.3. Mexico Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
  • 7.4.2. Europe
    • 7.4.2.1. France Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.2.2. Germany Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.2.3. United Kingdom Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.2.4. Italy Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.2.5. Spain Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.2.6. Rest of Europe Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.3.2. Japan Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.3.3. India Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.3.4. Australia Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.3.5. South Korea Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.3.6. Rest of Asia-Pacific Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.4.2. Africa Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)
    • 7.4.4.3. South America Venous Thromboembolism Treatment Devices Market Size in USD million (2022-2032)

8. Venous Thromboembolism Treatment Devices Market Company and Product Profiles

• 8.1. Abbott
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Boston Scientific Corporation
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. AngioDynamics
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Argon Medical Devices
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. Penumbra, Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Thrombolex
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Imperative Care Inc.
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Koninklijke Philips N.V.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Arjo
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Stryker
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. Cook
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. BIOCOMPRESSION SYSTEMS
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Medtronic
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. DSMAREF CO.LTD
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Teleflex Incorporated
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Surmodics Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. ICE Aspiration System
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. VentiV Scientific
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Inquis Medical
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Cardinal Health
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us